眼科 ›› 2024, Vol. 33 ›› Issue (1): 39-45.doi: 10.13281/j.cnki.issn.1004-4469.2024.01.007

• 论著 • 上一篇    下一篇

玻璃体切除联合玻璃体注射不同剂量曲安奈德治疗特发性黄斑前膜6个月的疗效观察

陈菲  邱研  唐蕾蕾  何慧君  王兵  高峰   

  1. 滕州市中心人民医院眼科,山东滕州 277500
  • 收稿日期:2023-08-13 出版日期:2024-01-25 发布日期:2024-02-06
  • 通讯作者: 高峰,Email:gaofengfm@163.com
  • 基金资助:
    山东省枣庄市科技发展计划(2022NS39)

Six months efficacy of vitrectomy combined with different dosage intravitreal injection of triamcinolone acetonide for idiopathic macular

Chen Fei, Qiu Yan, Tang Leilei, He Huijun, Wang Bing, Gao Feng   

  1. Department of Ophthalmology, Tengzhou Central People Hospital, Tengzhou Shandong 277500, China
  • Received:2023-08-13 Online:2024-01-25 Published:2024-02-06
  • Contact: Gao Feng, Email: gaofengfm@163.com
  • Supported by:
    Science and Technology Development Plan of Zaozhuang Shandong (2022NS39)

摘要: 目的 探讨25G玻璃体切除术联合不同剂量玻璃体曲安奈德注射(IVTA)对特发性黄斑前膜(iERM)患者的疗效及安全性。随机对照试验。研究对象 2022年4月至2022年10月于滕州市中心人民医院眼科确诊的iERM患者60例(60眼)。 方法 采用随机数字表法将患者随机分为玻璃体切除术联合IVTA 1 mg组20例(20眼)、玻璃体切除术联合IVTA 2 mg组20例(20眼)和单纯玻璃体切除术组(对照组)20例(20眼)。分别于术前及术后1、3、6个月采用国际标准小数视力表测量最佳矫正视力(BCVA)、非接触眼压计测量眼压、相干光断层扫描(OCT)测量黄斑中心凹厚度(CMT)并评价是否存在视网膜内层紊乱(DRIL)。计数资料、等级资料组间比较采用卡方检验,计量资料BCVA、CMT、眼压组间比较符合正态分布采用单因素方差分析,否则采用Kruskal-Wallis H检验。组内治疗前后BCVA、CMT的比较采用Friedman检验。主要指标 BCVA、眼压、CMT、DRIL。 结果 术后1、3个月, IVTA 1 mg组、IVTA 2 mg组的手术前后BCVA差值较对照组高,且CMT也低于对照组(P均<0.05),IVTA 1 mg组和IVTA2 mg组之间无统计学差异(P>0.05)。术后6个月,三组间BCVA、CMT及DRIL均无统计学差异(P均>0.05)。玻璃体切除联合2 mg IVTA组中有3例患者(15%)在术后1个月时眼压有不同程度的升高,用药后均降至正常。结论 玻璃体切除术联合IVTA 1 mg或2 mg可以加速iERM患者术后视力的改善及黄斑中心凹厚度的降低,但并不能改善患者的长期预后,IVTA 1 mg和IVTA 2 mg相比疗效相似,但IVTA 1 mg更安全。(眼科,2024, 33: 39-45)

关键词: 特发性黄斑前膜, 玻璃体切除术, 曲安奈德

Abstract: Objective To investigate the effect and safety of 25-gauge vitrectomy combination with different dosage of intravitreal injection of triamcinolone acetonide (IVTA) for the treatment of the patients with idiopathic macular epiretinal membrane (iERM). Design Randomized controlled trial. Participants From April to October 2022, sixty eyes of 60 patients with iERM diagnosed by department of Ophthalmology at Tengzhou Central People’s Hospital were included. Methods The patients were classified randomly into vitrectomy combined with IVTA 1 mg group (20 eyes of 20 patients) and vitrctomy combined with IVTA 2 mg group (20 eyes of 20 patients) , and vitrectomy group (control group, 20 eyes of 20 patients). Before and 1, 3, 6 months after the surgery, best corrected visual acuity (BCVA, LogMAR) was measured using the international standard decimal visual acuity chart, intraocular pressure (IOP) was measured with non-contact tonometer, and central macular thickness (CMT), disorganization of retinal inner layers (DRIL) was assessed using the optical coherence tomography (OCT). Chi-square test was used for counted data and ranked data. One-way ANOVA was used for measurement data conforming to normal distribution, otherwise Kruskal-Wallis H test was applied. Comparison of BCVA and CMT before and after treatment within the group was performed using Friendman test. Main Outcome Measures BCVA, IOP, CMT, DRIL. Results One and three months after the surgery, the mean BCVA in vitrectomy combined with IVTA 1 mg and 2 mg group was higher than in vitrectomy group, and CMT was less than that in vitrectomy group (all P<0.05). But the difference was not statistically significant between vitrectomy combined with IVTA 1 mg group and IVTA 2 mg group (P>0.05). However, at 6 months postoperatively, there was no statistical differences among all the three groups regarding CMT, DRIL, and BCVA (all P>0.05). Three patients (15%) in the IVTA 2 mg group had varying degrees of IOP increase 1 month after surgery, all of which decreased to normal after medication. Conclusion Vitrectomy combined with IVTA 1 mg or 2 mg can accelerate postoperative visual improvement and CMT reduction in patients with iERM, but can not improve long-term prognosis. The effect of IVTA 1 mg is similar to that of IVTA 2 mg, but safer. (Ophthalmol CHN, 2024, 33: 39-45)

Key words:  idiopathic macular epiretinal membrane, vitrectomy, triamcinolone acetonide